News | Contrast Media | July 29, 2015

New Imaging Contrast Agents Light Up Thyroid and Parathyroid Glands during Surgery

Near-infrared agents help surgeons distinguish thyroid and parathyroids from surrounding tissue

NIR, contrast agents, thyroid, parathyroids, surgery, Frangioni, FLARE

Intraoperative image of thyroid (red) and parathyroids (green) in rats four hours after intravenous injection of targeted contrast agents. Image captured using the FLARE system. Image courtesy of Macmillan Publishers Ltd.

July 29, 2015 — Researchers funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) have developed two near-infrared (NIR) contrast agents that are efficiently taken up by the thyroid and parathyroid glands following intravenous injection. The researchers tested the contrast agents in rats and pigs and showed that they could be used to help distinguish the thyroid and parathyroid glands from surrounding tissue and from each other. Their findings appeared in the Jan. 5, 2015, issue of Nature Medicine.

The thyroid is a butterfly-shaped gland located in the front of the neck that controls the rate of many activities involved in metabolism. Directly behind the thyroid sit four parathyroid glands, which tightly control calcium levels in the blood; each is approximately the size of a grain of rice.

If the thyroid isn’t working properly, or if a tumor is present, surgery may be needed to remove all or part of the gland. While the thyroid and parathyroids can be located prior to surgery via ultrasound, once a patient is on the operating table surgeons have only their eyes and knowledge of anatomy to help them distinguish these important glands from other tissues in the body. Inability to do so can result in incomplete removal of the thyroid or inadvertent damage to the parathyroids, which can cause chronically low calcium levels.

“Proper identification of the thyroid and parathyroid glands during head and neck surgery is critical for avoiding accidental injury, but presents a significant challenge due to their small size and variations in location from patient to patient,” says Richard Conroy, Ph.D., director of the Division of Applied Science & Technology at NIBIB. “The innovative design and optimization of these contrast agents has the potential to lead to the development of other tissue-specific small molecule contrast agents. It’s a great example of how investing in the development of new imaging technologies can help overcome existing challenges in medicine.”

Upon intravenous injection, the new contrast agents are taken up by the thyroid and parathyroids, where they emit different wavelengths of NIR light. Although this light is invisible to the naked eye, it can be easily seen using a specially-designed NIR camera called FLARE. The FLARE camera shoots a color video of the surgical site and also captures the two NIR wavelengths to create a unique view in which the tissues that have taken up contrast agents glow brightly. In their experiments on rats and pigs, the researchers used FLARE to visualize the thyroid and parathyroid simultaneously.

The development of the contrast agents was led by John V. Frangioni, M.D., Ph.D., professor of medicine at Harvard Medical School, and Hak Soo Choi, Ph.D., associate professor of medicine at Harvard Medical School; chemical synthesis was performed at Georgia State University in the laboratory of Maged Henary, Ph.D.

Frangioni is also CEO of Curadel, a company he started in 2014 with the purpose of developing NIR contrast agents and imaging systems to help surgeons identify glands, blood vessels, nerves, lymph nodes, and tumors during operations.

“We’re giving surgeons the ability to find these structures through blood and through tissue, and in doing so, we’re bringing surgery into the 21st century,” said Frangioni.

The novel thyroid and parathyroid contrast agents differ significantly from most current NIR contrast agents, which are composed of two separate molecules linked together: a molecule that emits a fluorescent signal, called the fluorophore, and an antibody or small molecule that targets the tissue of interest.

“You can think of the fluorophore as a lightbulb,” said Frangioni. “The conventional way to create a targeted fluorophore is to take a targeting ligand, such as an antibody, and hook it up to the lightbulb to create a new hybrid molecule. That’s the way people have been doing it for 50 years.”

But hybrid molecules tend to be large, and large molecules aren’t easily cleared by the body. This is a problem, said Frangioni, because when fluorescent molecules are injected into the blood, only a small fraction are taken up by the tissue of interest; the rest continue to circulate through the blood until filtered either by the kidneys or liver and excreted from the body. If a molecule is too big to be filtered, it will stay in the bloodstream and continue to emit fluorescent signal. This background signal makes it harder for surgeons to see signal being emitted from the structure of interest.

With the new type of contrast agents, the targeting component is incorporated directly into the chemical structure of the fluorophore to reduce the overall size and encourage clearance. “We basically deconstruct the targeting molecule into little pieces and scatter them around the fluorophore so that in three dimensions it’s a very compact molecule,” said Frangioni, who coined the novel arrangement “structure-inherent targeting.”

Frangioni said another advantage of a single molecule as opposed to a larger hybrid molecule is that, in the future, it will be less difficult to manufacture. “It’s a lot easier to make a single molecule instead of having to make the lightbulb and make the targeting molecule and put the two together. For those of us who are developing drugs for commercialization, that’s a big deal. If you can cut the number of steps in half, that’s huge.”

For more information: www.nature.com

Related Content

Medivis Launches SurgicalAR Augmented Reality Platform
Technology | Advanced Visualization | February 14, 2019
Medical imaging and visualization company Medivis officially unveiled SurgicalAR, its augmented reality (AR) technology...
An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. 

Feature | Ultrasound Imaging | February 07, 2019 | Dave Fornell, Editor
Here is a list of six key trends in ul...
Medtronic Recalls Synergy Cranial Software and Stealth Station S7 Cranial Software
News | Procedure Navigation Systems | February 05, 2019
Medtronic is recalling the Synergy Cranial Software and StealthStation S7 Cranial Software used with the StealthStation...
Podcast | Cybersecurity | February 04, 2019
Cyber hackers pose a worsening threat to radiology and the rest of medical imaging.
The top article from January was about researchers in Sweden using computed tomography (CT) to image the soft tissue of an ancient Egyptian mummy’s hand down to a microscopic level. Non-destructive imaging of human and animal mummies with X-rays and CT has been a boon to the fields of archaeology and paleopathology. Most popular radiology articles and news in January 2019.

The top article from January was about researchers in Sweden using computed tomography (CT) to image the soft tissue of an ancient Egyptian mummy’s hand down to a microscopic level. Non-destructive imaging of human and animal mummies with X-rays and CT has been a boon to the fields of archaeology and paleopathology.

Feature | February 01, 2019 | A.J. Connell and Dave Fornell
February 1, 2019 — Here is the list of the most popular content on the Imaging Technology News (ITN) magazine website
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
In today’s digital environment, a radiologist only sees images saved and shared to the PACS, so a firm understanding of X-ray reject rates is crucial for high image quality and good workflow.

In today’s digital environment, a radiologist only sees images saved and shared to the PACS, so a firm understanding of X-ray reject rates is crucial for high image quality and good workflow.

Feature | Digital Radiography (DR) | January 29, 2019 | By Jeff Zagoudis
X-rays were the first medical imaging technology to be invented, and they remain one of the most commonly performed e
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Artificial intelligence, also called deep learning and machine learning, was the hottest topic at the 2018 Radiological Society of North America (RSNA)) meeting.

Artificial intelligence was the hottest topic at the 2018 Radiological Society of North America (RSNA)) meeting, which included a large area with its own presentation therater set asside for AI vendors.

Feature | Artificial Intelligence | January 10, 2019 | Dave Fornell, Editor
Hands down, the hottest topic in radiology the past two years has been the implementation of...
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help